chemo generations

@primek      i got the dense breast excuse too & my  tumor was huge! 😄 the other  breast had no cancer so I would of thought they should of looked somewhat different, dense breast tissue or not

@beccabecca Yes I agree regarding the screen test etc. My mammogram was negative 5 weeks before a lump felt. Couldn't be seen fue to breast density. Is my survival really different. I doubt it in this case.

@kezmusc  thanks for sharing the link. I'll have a look 😊

@beccabecca,

It's the type of chemo drug used and the density.  ACT is 3rd generation.  There is a bit of a study here if you are interested.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538915/

@sister thanks for that, I also had invasive lobular, I did think that the predict tool was a bit vague, didn't allow for type of cancer & also I would think the % growth rate wld matter as well, not just if it's positive or negative. I only looked because my oncologist avoids the question when I ask.
Thanks 
 

@primek      thanks for that. Yes I did look at predict tool, but thought it odd that the way your cancer was detected can affect your possible survival chance outcome, esp as  mammograms give false results. & it doesn't ask for both ER & PR results. 
Thanks again 

I was wondering that, too but it sounds as if maybe it's got to do with the combination of chemo???  Just be aware @beccabecca that the Predict tool apparently doesn't predict well for all BC types.  I know that my onc said I was welcome to look at it but due to ILC being less common, the results would not be an accurate indicator.

I should say that I was on the same regimen as you - AC-T.

Does 'generation' here mean a time thing, as in age of the type of chemotherapy? A later invented chemo being a later generation?

Geeze I put that badly. It's late. I hope you get what I mean!

It's 3rd generation based on "predict" information for professionals, I'm guessing this is why you are asking:

Using PREDICT

The model is easy to use following data entry for an individual patient including patient age, tumour size, tumour grade, number of positive nodes, ER status, HER2 status, KI67 status and mode of detection. Survival estimates, with and without adjuvant therapy, are presented in visual and text formats. Treatment benefits for hormone therapy and chemotherapy are calculated by applying relative risk reductions from the Oxford overview to the breast cancer specific mortality. Predicted mortality reductions are available for both second generation (anthracycline-containing, >4 cycles or equivalent) and third generation (taxane-containing) chemotherapy regimens.

@primek
@SoldierCrab
@Jenny_BCNA

Can you offer assistance with this post

Thanks